Free Trial
OTCMKTS:CYYNF

Cynata Therapeutics (CYYNF) Stock Price, News & Analysis

Cynata Therapeutics logo
$0.19
0.00 (0.00%)
(As of 10/31/2024 ET)

About Cynata Therapeutics Stock (OTCMKTS:CYYNF)

Key Stats

Today's Range
$0.19
$0.19
50-Day Range
$0.19
$0.19
52-Week Range
$0.11
$0.19
Volume
N/A
Average Volume
200 shs
Market Capitalization
$27.22 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Cynata Therapeutics Limited, together with its subsidiaries, develops and commercializes proprietary induced pluripotent stem cell and mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. The company's lead therapeutic product candidate is CYP-001, which has completed Phase I clinical trial for the treatment of graft versus host disease. It also develops CYP-004, which is in Phase III clinical trial used for the treatment of osteoarthritis; and CYP-006TK, a novel polymercoated silicon wound dressing for diabetic wounds. In addition, the company develops products for the treatment of asthma, heart attack, coronary artery disease, brain cancer, sepsis, acute respiratory distress syndrome, critical limb ischemia, idiopathic pulmonary fibrosis, and renal transplantation. Cynata Therapeutics Limited has a strategic partnership with Fujifilm to provide clinical and commercial manufacturing services for, and supply of, Cynata's Cymerus therapeutic mesenchymal stem cell products. The company was formerly known as Eco Quest Limited and changed its name to Cynata Therapeutics Limited in October 2013. Cynata Therapeutics Limited was incorporated in 2003 and is based in Cremorne, Australia.

Receive CYYNF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cynata Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CYYNF Stock News Headlines

Cynata Therapeutics Limited (CYYNF)
The secret supplier behind NVIDIA, Tesla and Microsoft
The Biggest AI firms in the world...Tesla... Microsoft... NVIDIA... Are all relying on a little-known supplier, which provides a crucial building block for AI.
First Patient Treated in Phase 2 GvHD Trial
Jefferies Reaffirms Their Buy Rating on C4 Therapeutics (CCCC)
See More Headlines

CYYNF Stock Analysis - Frequently Asked Questions

Cynata Therapeutics' stock was trading at $0.0720 at the start of the year. Since then, CYYNF stock has increased by 163.9% and is now trading at $0.19.
View the best growth stocks for 2024 here
.

Shares of CYYNF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Company Calendar

Today
10/31/2024
Fiscal Year End
6/30/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Sanitary paper products
Sub-Industry
N/A
Current Symbol
OTCMKTS:CYYNF
CIK
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Market Cap
$27.22 million
Optionable
Not Optionable
Beta
0.43
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

This page (OTCMKTS:CYYNF) was last updated on 10/31/2024 by MarketBeat.com Staff
From Our Partners